Health Professionals

Dr Robert on the Role of Adjuvant Anti–PD-1 Therapy in Resected Stage IIB/C Melanoma

Caroline Robert, MD, PhD, head, Dermatology Unit, Gustave Roussy, discusses the role of adjuvant anti–PD-1 therapy in the treatment of patients with resected stage IIB/C melanoma, highlighting findings from the phase 3 KEYNOTE-716 (NCT03553836) and CheckMate 76K (NCT04099251) trials that have informed treatment decisions in this setting.

Read More

Metastatic Melanoma Study Finds Immunotherapy Resistance Mutations in Immune-Linked Genes

NEW YORK – A research team led by investigators at the Dana-Farber Cancer Institute and the Broad Institute has uncovered somatic mutations linked to immunotherapy resistance in metastatic melanoma patients who experienced disease recurrence and acquired drug resistance after an initial response to immune checkpoint immunotherapy (ICI).

Read More
MRV News
Melanoma News
Archive
Menu